Market News

Ironwood Pharmaceuticals, Inc. (IRWD) Analysts See $-0.16 EPS; LIQUEFIED NATURAL GAS LTD ORDINARY SHARE (LNGLF) Shorts Increased By 33.92%

Liquefied Natural Gas Limited (OTCMKTS:LNGLF) Logo

LIQUEFIED NATURAL GAS LTD ORDINARY SHARE (OTCMKTS:LNGLF) had an increase of 33.92% in short interest. LNGLF’s SI was 425,200 shares in April as released by FINRA. Its up 33.92% from 317,500 shares previously. With 166,600 avg volume, 3 days are for LIQUEFIED NATURAL GAS LTD ORDINARY SHARE (OTCMKTS:LNGLF)’s short sellers to cover LNGLF’s short positions. The SI to LIQUEFIED NATURAL GAS LTD ORDINARY SHARE’s float is 0.11%. The stock increased 0.20% or $0.001 during the last trading session, reaching $0.345. About 118,567 shares traded. Liquefied Natural Gas Limited (OTCMKTS:LNGLF) has 0.00% since April 21, 2017 and is . It has underperformed by 11.55% the S&P500.

Analysts expect Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) to report $-0.16 EPS on May, 14.They anticipate $0.17 EPS change or 51.52% from last quarter’s $-0.33 EPS. After having $-0.14 EPS previously, Ironwood Pharmaceuticals, Inc.’s analysts see 14.29% EPS growth. The stock decreased 1.65% or $0.29 during the last trading session, reaching $17.28. About 1.16 million shares traded. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has declined 11.53% since April 21, 2017 and is downtrending. It has underperformed by 23.08% the S&P500.

Liquefied Natural Gas Limited, together with its subsidiaries, engages in the identification and progression of opportunities for the development of liquefied natural gas projects to facilitate the production and sale of LNG in Australia, Canada, and the United States. The company has market cap of $172.33 million. It operates through LNG Infrastructure, and Technology and Licensing divisions. It currently has negative earnings. The companyÂ’s projects include the Magnolia LNG project located in Lake Charles, Louisiana, the United States; the Bear Head LNG Project located in Point Tupper, Richmond County, Nova Scotia, Canada; and the FishermanÂ’s Landing LNG project located in the Port of Gladstone, Queensland, Australia.

Investors sentiment decreased to 1.05 in Q4 2017. Its down 0.20, from 1.25 in 2017Q3. It turned negative, as 18 investors sold Ironwood Pharmaceuticals, Inc. shares while 44 reduced holdings. 21 funds opened positions while 44 raised stakes. 149.98 million shares or 2.99% less from 154.60 million shares in 2017Q3 were reported. 18.92M are held by Wellington Management Grp Limited Liability Partnership. Broderick Brian C holds 487,065 shares or 2.67% of its portfolio. Rock Springs Cap Mngmt Lp has invested 0.15% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). 206,186 are held by Wells Fargo Com Mn. Employees Retirement Association Of Colorado invested in 29,027 shares or 0% of the stock. Macquarie reported 59,128 shares. Park West Asset Management Limited Liability Corporation reported 0.42% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Employees Retirement System Of Texas stated it has 105,000 shares or 0.02% of all its holdings. Us Bancorp De stated it has 0% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Legal & General Grp Public Limited Liability Co has invested 0% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Goldman Sachs Group holds 0% or 449,964 shares. Amalgamated Financial Bank, New York-based fund reported 18,278 shares. Sei Invs Co reported 245,031 shares stake. Moreover, Ubs Asset Americas Inc has 0.08% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 6.36M shares. Alps Advsr has invested 0.02% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD).

Since January 24, 2018, it had 0 buys, and 7 sales for $1.22 million activity. The insider McHugh Julie sold $21,090. Currie Mark G had sold 1,634 shares worth $23,954. On Wednesday, February 21 Consylman Gina sold $52,688 worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) or 3,594 shares. $49,008 worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) was sold by MCCOURT Thomas A on Wednesday, February 21. $113,483 worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) was sold by Gilbert Halley E. $28,100 worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) was sold by OLANOFF LAWRENCE S.

Among 16 analysts covering Ironwood Pharmaceuticals (NASDAQ:IRWD), 5 have Buy rating, 2 Sell and 9 Hold. Therefore 31% are positive. Ironwood Pharmaceuticals had 39 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was maintained by Mizuho on Friday, October 6 with “Buy”. The firm has “Buy” rating given on Thursday, July 20 by Mizuho. The firm has “Buy” rating by Mizuho given on Friday, July 15. The rating was maintained by Barclays Capital with “Equal Weight” on Wednesday, February 22. Goldman Sachs initiated Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Monday, March 21 with “Neutral” rating. J.P. Morgan downgraded the stock to “Hold” rating in Friday, July 21 report. The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) earned “Buy” rating by Cowen & Co on Friday, August 4. The firm has “Neutral” rating by Wedbush given on Friday, February 19. The rating was upgraded by Cowen & Co on Wednesday, April 6 to “Outperform”. The firm earned “Hold” rating on Tuesday, January 9 by Mizuho.

Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company has market cap of $2.61 billion. The firm markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States and Constella name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout under ZURAMPIC and DUZALLO names. It currently has negative earnings. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, China, Hong Kong, and Macau; and license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, chronic constipation, and other GI conditions in Japan.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *